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Meglumine Exerts Protective Effects against Features of
Metabolic Syndrome and Type II Diabetes
Arturo Bravo-Nuevo1*, Alice Marcy2, Minzhou Huang1, Frank Kappler2, Jennifer Mulgrew1, Lisa LauryKleintop1, Melvin Reichman3, Annette Tobia2, George C. Prendergast1
1 Lankenau Institute for Medical Research (LIMR), Wynnewood, Pennsylvania, United States of America, 2 Dynamis Pharmaceuticals Co. Inc., Jenkintown, Pennsylvania,
United States of America, 3 LIMR Chemical Genomics Center Inc., Wynnewood, Pennsylvania, United States of America

Abstract
Metabolic syndrome, diabetes and diabetes complications pose a growing medical challenge worldwide, accentuating the
need of safe and effective strategies for their clinical management. Here we present preclinical evidence that the sorbitol
derivative meglumine (N-methyl-D-glucamine) can safely protect against several features of metabolic syndrome and
diabetes, as well as elicit enhancement in muscle stamina. Meglumine is a compound routinely used as an approved
excipient to improve drug absorption that has not been ascribed any direct biological effects in vivo. Normal mice (SV129)
administered 18 mM meglumine orally for six weeks did not display any gastrointestinal or other observable adverse effects,
but had a marked effect on enhancing muscle stamina and at longer times in limiting weight gain. In the established KK.CgAy/J model of non-insulin dependent diabetes, oral administration of meglumine significantly improved glycemic control
and significantly lowered levels of plasma and liver triglycerides. Compared to untreated control animals, meglumine
reduced apparent diabetic nephropathy. Sorbitol can improve blood glucose uptake by liver and muscle in a manner
associated with upregulation of the AMPK-related enzyme SNARK, but with undesirable gastrointestinal side effects not
seen with meglumine. In murine myoblasts, we found that meglumine increased steady-state SNARK levels in a dosedependent manner more potently than sorbitol. Taken together, these findings provide support for the clinical evaluation
of meglumine as a low-cost, safe supplement offering the potential to improve muscle function, limit metabolic syndrome
and reduce diabetic complications.
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gastrointestinal distress and diarrhea[9–11]. Moreover, under
diabetic conditions, accumulation of sorbitol in certain tissues,
where it is only slowly cleared by the polyol pathway, may
promote diabetic complications including atherosclerosis, cataracts, nerve damage and retinopathy [12].
Meglumine (N-methyl-D-glucamine) is a poorly metabolized
[13] derivative of sorbitol that has regulatory acceptance as a
benign excipient for drug formulation to increase aqueous
solubility of lipophilic drugs and improve their absorption.
Meglumine synthesis is simple and inexpensive, and, in several
decades of clinical use, it has never been ascribed either
detrimental or beneficial effects in patients or in vivo animal
studies. In vitro studies have shown that meglumine can reduce
oxidative damage in human fibroblasts cultured in a 3-deoxyglucosone (3DG) rich environment and increase fibroblast migration
[14,15]. Based on its structural similarity with sorbitol, we
investigated whether meglumine may stimulate SNARK levels
and exert muscle-associated protective effects against metabolic
syndrome or diabetes-associated conditions in a preclinical mouse
model of insulin-resistant diabetes.

Introduction
Physical exercise can help control glucose levels in individuals
with metabolic syndrome or type II diabetes, triggering two
different pathways of glucose uptake in skeletal muscle. One
pathway involves well-established mechanisms controlled by
insulin [1,2], whereas the other involves little understood muscle
contraction-related mechanisms that are independent of insulin
[2,3]. In recent work, muscle contraction has been reported to
increase the activity of the AMPK-related enzyme SNARK (also
known as NUAK2/ARK5), a kinase related to the master
regulatory kinase AMPK that responds to metabolic stress [4,5].
Mice that are genetically heterozygous for SNARK exhibit poor
glycemic control, hyperinsulinemia, elevated plasma and liver
triglycerides along with an increased body mass [6,7]. Sorbitol is a
slowly absorbed sugar alcohol derived from glucose and found in
certain fruits [8]. It stimulates SNARK activity and increases
glucose uptake by muscle cells [6]. Sorbitol has been explored as a
supplement to increase glucose uptake in diabetic individuals, but
its clinical use is impractical because its oral administration causes
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Materials and Methods

Lipid Analysis

This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by The Lankenau Institute for Medical
Research Institutional Animal Care and Use Committee approved
(Permit Number: A11-2997).

Triglyceride levels were measured in mice using colorimetric
assays. For this, lipids were extracted, from serum and liver, as
described by Naik et al [18]. Briefly, after extraction and
evaporation, the lipid layer was resuspended in 0.25 ml 1%
Triton X-100. Triglyceride concentrations were then determined
using the L-Type Triglyceride M enzymatic based assay kit (Wako
Chemicals, Richmond VA). Results for liver tissue were expressed
as microgram triglycerides per mg tissue.

Animals

Western Analysis

KK.Cg-Ay/J mice develop type 2 diabetes by 8 wk of age as
characterized by onset of hyperglycemia, hyperinsulinemia,
glucose intolerance and obesity [16]. 4–6 week old KK.Cg-Ay/J
mice (n = 20 per group) were given water ad libitum with or without
18 mM meglumine hydrochloride (salt prepared from commercial
meglumine obtained from Sigma, St. Louis, MO), kept in 12 hr
night/day light cycles and fed ad libitum. Equal numbers of female
and male animals were used.

C2C12 mouse myoblasts were cultured in Dulbecco’s modified
Eagle medium (DMEM) (Mediatech, Manassas VA) containing
10% fetal bovine serum (Hyclone, Logan, UT), and maintained at
37uC in a humidified 5% CO2 atmosphere. Cells treated with or
without meglumine at the concentrations and for the times
indicated were harvested by scraping, washing twice in PBS and
lysing in RIPA buffer containing protease and phosphatase
inhibitors. Equal protein for each sample (typically 50 mg/lane)
was separated by SDS–PAGE and transferred to Immobilon-P
membranes (Millipore, Billerica MA). Blots were incubated with
primary antibodies as recommended by the vendor (dilution
1:1000) and were detected with HRP conjugated secondary
antibodies using the enhanced chemilumescent reagents (Pierce,
Rockford IL) according to the manufacturer’s instructions.
Primary antibodies used were for SNARK (also known as
NUAK2), MYPT1, phospho-MYPT1 (Ser507), phospho-MYPT1
(Ser668), phospho-MYPT1 (Thr696), (Cell Signaling Technology,
Beverly, MA), Glut1 (Abcam, Cambridge, MA), AMPK (Millipore, Temecula, CA) and ß-actin (Santa Cruz Biotechnology,
Santa Cruz, CA).

Ethics Statement

Glucose Measurement
Diabetes was confirmed in KK.Cg-Ay/J mice by blood glucose
measurement using a ‘‘One Touch’’ blood glucose monitoring
system (Lifescan, Milpitas, CA). Animals were considered hyperglycemic when, after a 4 hr fast, their blood glucose levels were
above 250 mg/dl.

Mesh Grip Test
Mice (SV129) (n = 15 per group) were treated with or without
meglumine (18 mM in drinking water), for at least 30 days were
placed on a mesh wire cage 50 cm above a cage filled with soft
bedding. After adjustment to this new environment for 3–5
seconds, the cage was slowly inverted. Before the cage was
inverted, the investigator visually confirmed that the animal was
gripping the wire mesh on the cage with all limbs. After cage
inversion, the grip time on the mesh wire cage before falling was
recorded. This test was repeated 3 times for all mice with a 24 hr
resting period between tests. The mean time mice held their grip
on the mesh cage, while inverted, was employed as simple
indicator of muscle strength [17].

Statistical Analysis
Values shown are means 6 standard error of the means (SE).
The significance of the differences between the two groups was
analyzed by a student’s t test. P values of 0.05 or less were defined
as statistically significant.

Results
Meglumine Stimulates SNARK in Myoblasts
Sorbitol-induced glucose uptake in muscle requires SNARK
stimulation [6]. Given the close structural relationship of
meglumine to sorbitol we asked whether the former might also
stimulate SNARK. Murine C2C12 myoblasts were treated with
sorbitol or meglumine for different times and concentrations.
SNARK expression levels were determined by Western analysis.
Steady-state levels of SNARK protein increased in a dosedependent manner after 60 min of treatment with meglumine
(Fig. 1A). This effect reached a plateau at 30 minutes of such that
further increasing the time or concentration of meglumine did not
further increase SNARK expression levels. The stimulatory effect
of meglumine on SNARK levels was more potent and longer
lasting than that produced by sorbitol (Fig. 1B). The increase in
SNARK expression induced by meglumine was associated with an
increase in phosphorylation of Ser507 on myosin phosphatase
target subunit 1 (MYPT1) (Fig. 1C), a SNARK substrate [19] that
regulates myosin light chain kinase and reinforces its effects on
actin stress fiber formation and muscle contraction by the Rho
kinase ROCK. In contrast, MYPT1 Ser668 or Thr696, which are
also phosphorylated by ROCK appeared to be unaffected
(Fig. 1C). To further establish the specificity of meglumine in
affecting SNARK levels, we compared the effects of the amino
sugar glucosamine (2-amino-2-deoxy-glucose), a structurally relat-

Nephropathy Analysis
Kidneys were examined from KK.Cg-Ay/J animals that had
been hyperglycemic for 7 months. Renal slices were fixed in 4%
paraformaldehyde, embedded in paraffin and deparaffinized in
xylene before preparation of 4 mm sections and staining with
hematoxylin-eosin, periodic acid Schiff (PAS) and Masson
trichrome. The pathologist who scored the extent of renal injury
was blind to the treatment groups. The score was based on
morphometric analysis of the glomerular disease and interstitial
fibrosis. A rating scale from 0 to 4 was used with 0 meaning
normal appearance and 4 meaning very severe lesions.

Glucose Challenge
After animals had fasted for 4 hrs, their basal glucose level was
measured using a ‘‘One Touch’’ blood glucose monitoring system
(Lifescan). They were then injected intraperitoneally (IP) with 1 g/
Kg body weight of 10 mg/ml D-glucose in PBS. Blood glucose
levels were measured at 15, 30, 60 and 120 minutes following
injection.

PLOS ONE | www.plosone.org

2

February 2014 | Volume 9 | Issue 2 | e90031

Meglumine Protects against Diabetic Effects

time that control or meglumine-treated mice could grasp an
inverted metal grid. This test was performed on each mouse once a
day for several days, to permit sufficient rest between trials. We
observed that meglumine-treated mice could suspend themselves
above the cage significantly longer (17.8 sec) than mice in the
untreated control group (6.3 sec) (Fig. 2A). This observation
supported the notion that meglumine may affect muscle function
in vivo. Since meglumine could elevate levels of SNARK in
murine myocytes in vitro, we evaluated the levels of SNARK
in vivo in skeletal muscle obtained from the thigh of mice
euthanized at the experimental endpoint. Western analysis from
four subjects in each group revealed variable but consistent
upregulation in the steady-state levels of SNARK in the thigh
muscle from meglumine-treated mice (Fig. 2B). While we did not
explore stamina at longer treatment times, starting at 22 weeks we
observed a significant trend toward lower weight in megluminetreated mice compared to control mice receiving plain water
(Fig. 2C). Together, these observations provided in vivo support
for the hypothesis that meglumine may favorably influence muscle
function and perhaps overall metabolic physiology at some level.

ed nontoxic sugar. In contrast to meglumine, glucosamine did not
stimulate SNARK expression (Fig. 1D). Finally, both meglumine
and sorbitol caused an increase in the expression levels of glucose
transporter Glut1, peaking at 10 mM treatment (Fig. 1E). Taken
together, these observations prompted us to examine whether
meglumine might affect muscle function or blood levels of glucose
in vivo.

Meglumine Lacks Diarrheal Effects but Increases Muscle
Stamina and Limits Weight Gain in a Manner Associated
with Steady-state Elevation of SNARK in Muscle
SNARK expression relates directly to muscle contraction and
the activity of the Glut1 glucose transporter in muscle cells [6].
Since meglumine elevated SNARK expression in mouse C2C12
myoblasts, we investigated its effects in normal mice administered
the compound at 18 mM in drinking water. This concentration
was chosen from previous pilot studies based on pharmacokinetic
analyses in rodents [13]. Starting an the age of 6 weeks, mice that
received meglumine orally in their drinking water for a period of
12 weeks did not exhibit any change in their water consumption
compared to control animals (Fig. S1). Further, meglumine-treated
animals exhibited no signs of diarrhea (unpublished observations),
which is the primary gastrointestinal side-effect produced by oral
administration of sorbitol which prevents its clinical use.
Since meglumine elevated SNARK in myoblasts, and SNARK
has been suggested to cooperate with Rho/ROCK signaling to
promote actin fiber formation and muscle contraction [19,20], we
reasoned that meglumine treatment might provide a benefit to
muscle stamina. To explore this notion, we compared the length of

Meglumine Improves Glycemic Control and Reduces
Plasma Triglycerides in Diabetic Mice
Previously published studies have shown that SNARK heterozygote mice exhibit increased body weight, poor glycemic control,
accumulated fat in liver and increased triglycerides in serum [6].
Based on the ability of meglumine to affect SNARK levels and
muscle stamina, we assessed the compound’s effects on these
parameters in KK.Cg-Ay/J mice, an established model of type II

Figure 1. Meglumine increases SNARK levels in myoblasts. Panels show the results of Western analyses of total protein isolated from C2C12
murine myoblasts treated with meglumine, sorbitol or glucosamine at various concentrations and times. Actin levels were used as a control for equal
protein loading in the gel lanes. A: Cells were treated with varying amounts of meglumine for 60 minutes (left side) or 200 mM meglumine for varying
times (right side). B: Myoblasts were treated with various levels of meglumine or sorbitol for 30 min (left panel) or with 200 mM meglumine or
sorbitol for various times (right panel). C: Cells were treated with varying amounts of meglumine or sorbitol for 60 minutes before analysis of the
levels of SNARK or total or phospho-specific levels of its substrate MYPT1 phosphorylated at Ser507, Ser668 or Thr696. D: Cells were treated with
varying amounts of meglumine or glucosamine for 60 minutes before analysis of SNARK levels.
doi:10.1371/journal.pone.0090031.g001
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Figure 2. Positive effect of meglumine on skeletal muscle strength and weight gain. A: Control and meglumine-treated normoglycemic
mice were subjected to a ‘hang test’ to measure strength. Meglumine treated mice (black bar) performed significantly better than control-treated
animals, with the former group averaging 17.8 seconds of hanging time and the control group averaging 6.3 seconds. Values are mean 6 SE with
n = 15 for each group. P,0.001. B: Effect of meglumine in SNARK expression in skeletal muscle. Western analysis was conducted on total protein from
tissue extracts prepared from dissected thigh muscle of animals euthanized at the experimental endpoint. C: Long term treatment with meglumine
limits weight gain. Animals were weighed at the times indicated starting 8 weeks after initiation of 18 mM meglumine in drinking water. Asterisk
designates P,0.05.
doi:10.1371/journal.pone.0090031.g002

diabetes where hyperglycemia and insulin resistance develop by 2
months of age accompanied by nephropathy, fat accumulation in
liver and increased serum triglycerides [16]. To assess long-term
effects, mice were treated for 7 months with 18 mM of meglumine

in drinking water as before and compared with an untreated
control group. The KK.Cg-Ay/J model is not ideal to assess
survival, but at this endpoint we observed no significant difference
in the numbers of animals in each cohort.
Mice treated with meglumine did not avoid the drinking water
containing meglumine and their fluid consumption was similar to
the untreated group during the course of the trial (Fig. S1).

Figure 3. Meglumine improves glucose tolerance. Control
(dashed line, open triangles) or meglumine-treated KK.Cg-Ay/J mice
(solid line, closed squares) were injected i.p. with glucose (1 g/kg) and
blood glucose was measured after 15, 30, 60 and 120 minutes. Values
are mean 6 SE shown in the error bar; n = 8 for each group. Asterisk
designates P,0.05.
doi:10.1371/journal.pone.0090031.g003

PLOS ONE | www.plosone.org

Figure 4. Meglumine reduces hyperglycemia. The figure presents
the proportion of hyperglycemic mice that survived to the experimental
endpoint of 7 months after receiving drinking water that was either
untreated (left bar) or treated with meglumine (right bar).
doi:10.1371/journal.pone.0090031.g004

4

February 2014 | Volume 9 | Issue 2 | e90031

Meglumine Protects against Diabetic Effects

Meglumine Ameliorates Diabetic Nephropathy
KK.Cg-Ay/J mice quickly develop nephropathy and proteinuria, which is particularly acute in females, compared to other
diabetic murine models [16]. The renal pathology displayed
includes expansion and thickening of the mesangial matrix,
Bowman’s capsule and tubules; proteinuria; and an increase in
the albumin/creatinine ratio. In support of its beneficial effects on
glycemic control and hyperlipidemia, we observed a significantly
lower kidney weight in animals treated 7 months with meglumine.
Kidneys from treated mice weighed an average of 297+/2SD mg
compared to an average of 270+/2SD mg in the untreated
control group (Fig. 7). This difference was mainly in female mice,
where examination of a small number of subjects indicated a
higher albumin/creatinine ratio in urine consistent with kidney
pathology (data not shown). While both treated and untreated
groups showed high levels of proteinuria, the levels were markedly
higher in the untreated group. In further support of these
observations, a qualitative ranking of the severity of kidney
pathology showed a trend in the ability of meglumine to
ameliorate nephritis, hydronephrosis, atrophy-fibrosis and glomerulosclerosis in female mice (Table 1). Taken together, these
results furthered the evidence that meglumine exerted protective
effects against diabetes in retarding the severity of nephropathy
associated with diabetes. Overall, we concluded that meglumine
has a number of heretofore undescribed medicinal properties that
should be assessed clinically as a simple and possibly effective
treatment for diabetes, fatty liver disease, muscle fatigue or
metabolic syndrome.

Figure 5. Meglumine reduces fasting blood glucose levels.
KK.Cg-Ay/J mice treated with meglumine exhibited better glucose
control and overall lower glucose levels than untreated mice. Most
untreated hyperglycemic mice died between 3–7 months of age. Values
are mean 6 SE shown in the error bar. n = 20 for both groups (although
not all time-points included measurements from all animals in each
group). Asterisk designates P,0.05.
doi:10.1371/journal.pone.0090031.g005

Notably, after two months of treatment, meglumine-treated mice
performed better in a glucose tolerance test (Fig. 3), indicating that
their glucose management was superior to control mice. Consistent with this result, meglumine-treated animals were less likely to
exhibit hyperglycemia compared to their untreated peers (Fig. 4)
and their average fasting levels of glucose were significantly lower
(Fig. 5). In a coordinate manner, meglumine also significantly
lowered triglyceride levels in both the liver and blood serum when
compared with untreated mice (Fig. 6). Overall, these results
supported the conclusion that meglumine may exert protective
effects against the primary pathogenic drivers in diabetes and
metabolic syndrome, perhaps including fatty liver disease.

Discussion
Insulin, as well as other oral and injectable diabetes medications
combined with an exercise program, are the most common
therapies prescribed to reduce blood glucose levels in diabetic
patients. The mechanism by which glucose uptake occurs in
skeletal muscle is well-established in the case of insulin, but there
remain some gaps in knowledge concerning how skeletal muscle

Figure 6. Serum and liver triglycerides are lowered by meglumine treatment. Seven month old KK.Cg-Ay/J mice were analyzed in this
experiment having received drinking water that was untreated or treated with meglumine. A: Serum triglyceride levels. In untreated mice, levels were
,750–800 mg/dL (left bar, white) whereas meglumine-treated mice displayed significantly lower levels of ,300 mg/dL (right bar, black). Values
are mean 6 SE shown in the error bar. n = 10 for both groups. P = 0.00007. B: Liver triglyceride levels. Values are mean 6 SE shown in the error bar.
Water group, n = 10; meglumine group, n = 9. P = 0.043.
doi:10.1371/journal.pone.0090031.g006
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Table 1. Trend in amelioration of nephropathy by meglumine in female diabetic mice.

Nephritis

Hydronephrosis

Atrophy -Fibrosis

Glomerulosclerosis

Tubular Dilation

= Water (n = 3)

0.5060.0

2.3361.15

0.060.0

0.8361.04

0.3360.29

= Meg (n = 3)

0.5060.0

3.0060.0

1.0060.0

0.7560.35

2.0060.0

R Water (n = 7)

1.1460.63

0.5760.79

0.6460.48

0.7960.57

1.4360.53

R Meg (n = 6)

0.7560.76

0.1760.41

0.1760.26

0.5060.0

1.5860.92

Kidney sections obtained from KK.Cg-Ay/J mice treated with or without meglumine in their drinking water for seven months were examined blindly by a kidney
pathologist for evidence of nephritis, hydronephrosis, atrophy-fibrosis, glomerulosclerosis and tubular dilation. Severity was ranked qualitatively using a 0–4 scale where
0 = normal and 4 = severe lesion. The values presented in the Table represent the mean 6 SE using this scale. Females in this model exhibit more nephropathy than
males, the latter of which did not exhibit the beneficial trend seen in females. =, male; R, female; n, number of mice examined.
doi:10.1371/journal.pone.0090031.t001

contraction leads to glucose uptake. Recent work has suggested
that the AMPK-related kinase SNARK is a critical mediator of
skeletal muscle contraction-stimulated glucose uptake [6]. While
sorbitol can upregulate SNARK, its acute gastrointestinal sideeffects make it unsuitable for routine treatment of diabetic patients.
In this report, we documented the benefits of the sorbitol
derivative meglumine as a potentially superior tool to improve
glycemic control and muscle stamina and to delay the onset of
diabetic complications such as nephropathy. Meglumine is
regarded as safe by the U.S. FDA in concentrations as high as
100 mg/kg per day. It is commonly used as an excipient agent for
drug formulations and the production of pharmaceutical grade
material is inexpensive at less than US $300 per kg. Thus, the
known safety and low cost render the potential medicinal
properties of meglumine appealing to translate immediately to
clinical testing for treatment of metabolic syndrome, fatty liver
disease and diabetes, either independently or as an adjuvant
supplement to exercise. Indeed, given the observed positive effects
of meglumine on muscle stamina in mice, it is conceivable that this
compound may offer a novel supplement to safely enhance
strength or energy, and combat muscle fatigue in healthful or
disease settings.
Compared to its structural relative sorbitol, we have shown
meglumine to be a more potent stimulant of the AMPK-related
kinase SNARK, which is implicated in mediating muscle
contraction-induced glucose uptake [6]. In vivo tests revealed that
oral meglumine, administered at 18 mM in drinking water freely
consumed by animals in the present work, was safe, having no
observable side-effects such as the diarrhea caused by sorbitol.

Striking improvements in muscle stamina and weight control were
observed in normal mice and improved glycemic control with a
two-fold reduction in triglyceride levels in blood and liver was
documented in highly diabetic mice. Kidney damage was the
primary complication in the type II diabetes model we examined,
and meglumine significantly reduced the observed severity of
kidney damage in the model. Further work is required to
understand the relationship between these observations. SNARK
is a complex modifier of metabolic stress responses whose roles in
normal physiology and pathophysiology are poorly understood.
SNARK deficiency in mice is associated with increased body mass,
serum triglycerides, hyperglycemia and glucose intolerance [7],
but also increased physical activity and reduced inflammatory
markers [21]. In humans, SNARK levels have been reported to be
elevated in diabetic patients [22]. Our results warrant additional
study of how meglumine improves muscle stamina, elicits
cytoprotection in kidney of hyperglycemic rodents and improves
glucose regulation. Indeed, since ,20% of an administered oral
dose of meglumine is absorbed into the bloodstream of rodents or
dogs [13], further studies are warranted. For a better understanding of its apparent beneficial effects, observed in the present
studies, primary actions of this compound at the level of
gastrointestinal physiology and microbiome ecology should also
be considered.
On the basis of its ability in rats to reduce levels of 3DG, an
important driver of AGE accumulation in diabetes-associated
complications and aging, meglumine has been conceptualized as
an inhibitor of fructosamine-3-kinase (FN3K), the enzyme
responsible for generating the chemical precursors of 3DG
(A.T., F.K., A.M., unpublished data). In vitro studies also show
that meglumine can ameliorate oxidative stress in a 3DG-rich
environment, similar to what occurs in diabetic skin ulcers [15].
Our findings do not rule out such a role for meglumine, which
could conceivably contribute to the reduced nephropathy
observed in meglumine-treated animals. In a related vein, we do
not know whether the ability of meglumine to affect glycemic
control and hyperlipidemia actually reflects a direct effect on
muscle. Even if this is the case, it is possible these benefits may be
distally related, for example, by a direct impact on physical activity
in the animal (i.e. by stimulating exercise). In future investigations,
it will be important to assess the causal relations of meglumine on
the response of SNARK, muscle function and metabolic
parameters in diabetes, along with the precise molecular
mechanisms that explain its effects on muscle or other tissues.

Figure 7. Kidney weight in diabetic animals is reduced by
meglumine treatment. Kidney weights were measured postmortem
in KK.Cg-Ay/J mice euthanized 7 months after initiation of the
experiment. Untreated mice display higher kidney weights averaging
,290 mg (left bar, white) whereas meglumine-treated mice display
lower kidney weights averaging ,260 mg (right bar, black). Values
are mean 6 SE shown in the error bar. n = 20 in both groups. P = 0.017.
doi:10.1371/journal.pone.0090031.g007
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Supporting Information
Figure S1 Meglumine administration in drinking water
does not affect daily fluid intake. KK.Cg-Ay/J mice treated
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with meglumine (dashed line) showed no difference in daily fluid
intake when compared to the untreated KK.Cg-Ay/J mice (solid
line). Values are mean 6 SE shown in the error bar. Both groups
n = 20.
(TIFF)
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